Successful treatment of molecular relapse in NPM1-positive AML using 5-azacytidine.
Wermke
M
M
Thiede
C
C
Kiani
A
A
Ehninger
G
G
Bornhäuser
M
M
Platzbecker
U
U
D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D001374:Azacitidine / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000235:genetics; D008875:Middle Aged; D018365:Neoplasm, Residual; D009687:Nuclear Proteins / Q000032:analysis* / Q000235:genetics; D000090243:Nucleophosmin; D016315:Proto-Oncogene Proteins c-abl / Q000032:analysis; D012008:Recurrence
D000964:Antimetabolites, Antineoplastic; C000716967:NPM1 protein, human; D009687:Nuclear Proteins; D000090243:Nucleophosmin; D016315:Proto-Oncogene Proteins c-abl; D001374:Azacitidine